drugset / Trial / NCT05603572
KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
NLP-KAT-101 is a Phase 1/2a dose escalation and expansion study to investigate the safety, tolerability, PK, and preliminary efficacy of oral + intratumoral (IT) KAT in subjects with HCC.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2027-11
- Completion
- 2027-11
Outcome
Outcome not reported
Stopped (Enrollment): “Enrollment paused”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KAT-101 | Unknown | — | Oral |
| Subject | KAT-201 | Unknown | — | Intrathecal |